Loading quotes...
Forecast
The analysts' average price target is €2.82 (-7.54%). The median is €2.60 (-14.75%).
| Buy |
3 |
| Hold |
9 |
| Sell |
3 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Cronos Group hits 52-week high after strong Q2 results
The Cronos Group share rose to a 52-week high of $3.44, with a market capitalization of $1.25 billion and year-to-date performance of 25.86%. InvestingPro points to an overvaluation versus fair value. Cronos beat expectations in Q2 2026 with revenue of $53 million (expectation $44.73 million), adjusted EPS of $0.09 (expectation $0.01), gross profit of $28.5 million and adjusted EBITDA of $13.1 million; cash and investments amounted to $827 million, and $60 million in share buybacks were reported. » More on de.investing.com
Cronos shares rise after Q2 results significantly beat expectations
Cronos reported Q2 EPS of $0.09 (consensus $0.01) and revenue of $53.0 million versus expected $44.73 million. The company reported record net revenue, gross profit and adjusted EBITDA, organic revenue growth of 51% and record sales in Israel, Canada and Germany. Cronos repurchased a total of 12.3 million shares in H1 2026. The strong company-specific metrics pushed the stock sharply higher in pre-market trading and brought it closer to its 52-week high. » More on de.investing.com
Cronos Group names ATB Capital Markets as broker for share buyback program
Cronos Group has appointed ATB Capital Markets Corp. (ATB Cormark) as broker for share repurchases on the Toronto Stock Exchange and other Canadian trading systems, replacing Virtu Canada Corp. The company gave no details on the reasons, size or timing of the buyback program. Cronos has most recently pursued an aggressive buyback strategy, which coincided with a 49% share price increase last year; market capitalization is around USD 1.04 billion. » More on de.investing.com
Cronos Group well above Q1 2026 forecasts; shares rise premarket
Cronos Group reported Q1 2026 EPS of $0.04 (expectation $0.02) and revenue of CAD 45.2 million, up 40% year over year. Gross profit rose to CAD 19.2 million, adjusted EBITDA to CAD 5.1 million, and the balance sheet remains debt-free. Growth was driven mainly by stronger sales in Canada and Israel. After the results, the stock climbed about 9.45% in premarket trading. » More on de.investing.com
Cronos to release results for quarter ended 31 March 2026 on 11 May 2026
Cronos will publish results for the quarter ended 31 March 2026 on 11 May 2026. Two analysts expect earnings per share of an average of 0.005 USD, after 0.030 CAD in the year‑ago quarter. Three analysts see revenue in the report at about 42.2 million USD versus 46.3 million CAD a year earlier. Four analysts expect, on average, earnings per share of 0.060 USD and revenue of about 191.2 million USD for the current fiscal year (prior year 204.8 million CAD). » More on finanzen.net
Financials
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 56.02m | 80.90% |
| Gross profit | 28.5m | 82.45% |
| Net profit | 12.19m | 44.90% |
| EBITDA | 16.85m | 35.26% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €1.19bn |
Number of shares | 368.41m |
52-week high/low | €3.50 - €2.04 |
| Dividends | No |
Beta | 1.20 |
P/E ratio | 22.45 |
PEG ratio | -0.01 |
P/B ratio | 1.24 |
P/S ratio | 6.45 |
Company profile
Cronos Group Inc. operates as a cannabinoid company. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones and Happy Dance brands in the United States. The company is also involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. It sells cannabis and cannabis products, including dried cannabis, pre-rolls, edibles, concentrates, and cannabis extracts through wholesale and direct-to-client channels under its wellness platform, PEACE NATURALS; and operates under adult-use brands, Spinach. It also exports dried cannabis and cannabis oils to Germany, Israel, and Australia. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.
| Name | Cronos |
| CEO | Michael Ryan Gorenstein |
| Headquarters | Stayner,
on Canada |
| Website | |
| Sector | Health Care |
| Industry | Health Care Providers & Services |
| IPO | 27/02/2018 |
| Employees | 610 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | CRON |
Toronto Stock Exchange | CRON.TO |
Frankfurt | 7CI.F |
Düsseldorf | 7CI.DU |
München | 7CI.MU |